secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001193125-24-275646
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV gains FDA alignment on Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years
--------------------------------------------------------------------------------

- FDA confirmed Phase 3 EPITOPE efficacy data serves as intermediate endpoint for Accelerated Approval.
- COMFORT Toddlers safety study on-track for 2Q 2025 start; will enroll ~480 subjects at 80-90 centers.
- Post-marketing confirmatory study criteria agreed; BLA submission for toddlers anticipated 2H 2026.
- Commercial Viaskin Peanut patch (used in 304 subjects OLE) deemed different product; no safety/efficacy differences vs clinical patch.
- Adhesion will be exploratory endpoint in COMFORT Toddlers, not co-objective; wear time data methodology aligned with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524275646/0001193125-24-275646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524275646/d857224d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-275646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer